Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: SCHIZOPHRENIA 1 (Disorder) Clear all
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP6981, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Glendale, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Healthy Volunteers, Schizophrenia
Interventions
TAK-041, TAK-041 Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 55 Years
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
ASP4345, Matching Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced May 21, 2026, 11:39 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Bipolar 1 Disorder, Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions
Aripiprazole, Ingestible Event Marker (IEM)
Drug · Device
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
12
States / cities
Cerritos, California • Garden Grove, California • Long Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 9072, Low dose, ALKS 9072, Med dose, ALKS 9072, High dose, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
6
States / cities
Atlanta, Georgia • Hoffman Estates, Illinois • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Schizophrenia
Interventions
10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 21, 2026, 11:39 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Suicide, Psychosis
Interventions
Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2023 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy
Interventions
PF-05180999
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Healthy Participants, Schizophrenia Diagnosis
Interventions
NTX-253, Placebo
Drug
Lead sponsor
Neurosterix
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
KarXT
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Los Alamitos, California • Hollywood, Florida • Miami Lakes, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 4 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
Interventions
clozapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
Hartford, Connecticut • Athens, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 11:39 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Schizophrenia
Interventions
14C-SEP-380135
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
Brexpiprazole (OPC-34712)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
13 Years to 17 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Little Rock, Arkansas • Culver City, California • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 11:39 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Interventions
Xanomeline and trospium chloride (KarXT)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
12
States / cities
Cerritos, California • Torrance, California • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia
Interventions
ALKS 3831
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Little Rock, Arkansas • Clementon, New Jersey • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Cognition, Healthy Participants
Interventions
Modafinil
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 35 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Seroquel IR 300mg, Seroquel IR 25mg, Quetiapine Formulation A 300mg, Quetiapine Formulation B 300mg, Quetiapine Formulation 25mg
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Schizophrenia
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Glendale, California • Long Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder
Interventions
Lurasidone HCl
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
2
States / cities
Glendale, California • Wichita, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced May 21, 2026, 11:39 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Hallucinations
Interventions
functional magnetic resonance imaging
Device
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced May 21, 2026, 11:39 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Schizophrenia, Schizoaffective, Bipolar Disorder 1
Interventions
Yoga-based Exercise (YE), Wellness Lifestyle Program (WLP)
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced May 21, 2026, 11:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-05180999, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced May 21, 2026, 11:39 PM EDT